SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vertex Pharmaceuticals (VRTX) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (583)4/25/2002 1:32:51 AM
From: Spekulatius  Read Replies (1) | Respond to of 1169
 
<< There were 285 adult patients enrolled in the study, of which 224 patients in the pralnacasan dose groups and 55 in the control group were available for evaluation.>>
Clearly this study was not designed to achieve statistical significance (if that were the case the control arm group should have been about as large than the pralnacasan arm). So this is not a bad result necessarily.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News